课题基金 / 基金详情

Cancer Photodynamic Therapy by use of RES-avoiding Liposomes

Cancer Photodynamic Therapy by use of RES-avoiding Liposomes
使用避免 RES 的脂质体进行癌症光动力治疗
批准号:
07672424
负责人:
OKU Naoto
金额:
$1.34万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996

项目摘要

项目成果

OKU Naoto的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Photodynamic therapy (PDT) as a cancer treatment is notable for its quite low side effects in comparison with those of chemotherapy and radiotherapy. However, the accumulation of porphyrin derivatives used in PDT into tumor tissues is rather low. Since long-circulating liposomes are known to accumulate passively into tumor tissues, we liposomalized a porphyrin derivative, benzoporphyrin derivative monoacid ring A (BPD-MA), and used such liposomes to investigate the usefulness of PDT for tumor-bearing mice. BPD-MA was liposomalized into glucuronate-modified liposomes, which are known to be long-circulating. These liposomes were injected i.v. into Balb/c mice bearing Meth A sarcoma, and tumor regression and survival time were monitored after irradiation with laser light. Tumor regression and complete curing of tumor were observed when long circulating liposomalized BPD-MA was injected and laser-irradiated. These results suggest that a long-circulating liposomal formulation of photo-sensitive agents is useful for PDT.We also determined the liposomal trafficking by use of positron emission tomography. RES-avoinding liposomes havging long-circulating character, namely glucuronic acid-midified or PEG-modified liposomes, started to accumulate in tumor quite early after i.v. injection. Part of BPD-MA in liposomes, however, transfered to lipoproteins in the plasma, altought the liposomal formulation was useful for PDT.Therefore, liposomalization of BPD-MA should be investigated further for getting practical liposomal photosensitizer for clinical use.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
Oku,N.et al.: "Application of Long-cirulating Liposomes to Cancer Photodynamic Therapy" Biol.Pharm.Bull.(in press). (1997)
Oku,N.等人:“长循环脂质体在癌症光动力治疗中的应用”Biol.Pharm.Bull.(正在出版)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Naoto Oku,et al.: "Effect of Serum Protein Binding on Real-time Trafficking of Liposomes with Different Charges Analyzed by Positron Emission Tomography." Biochim.Biophys.Acta,. (in press).
Naoto Oku 等人:“通过正电子发射断层扫描分析血清蛋白结合对不同电荷脂质体实时运输的影响”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Naoto Oku, Yoshihiro Tokudome, Hideo Tsukada, and Shoji Okada: "Real-time Analysis of Liposomal Trafficking in Tumor-bearing Mice by Use of Positron Emission Tomography" Biochim.Biophys.Acta. 1238. 86-90 (1995)
Naoto Oku、Yoshihiro Tokudome、Hideo Tsukada 和 Shoji Okada:“利用正电子发射断层扫描实时分析荷瘤小鼠的脂质体运输”Biochim.Biophys.Acta。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Oku, N. et al.: "Trafficking of Various Long-circulating Liposomes in Tumor-bearing Mice Determined by Positron Emission Tomography" Biophram. Drug Disposition. 17. 435〜441 (1996)
Oku, N. 等人:“通过正电子发射断层扫描确定荷瘤小鼠中各种长循环脂质体的运输”Biophram 17. 435-441 (1996)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
18
    Development of FA-Snap, a smart DDS drug, for proposing an innovative therapeutic modality of ischemic stroke.
    New development of diagnostic and therapeutic modality for ischemia/reperfusion injury by intelligent DDS
    • 批准号:
      23249005
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $30.7万
    • 财政年份:
      2011
    • 负责人:
      OKU Naoto
    • 依托单位:
    Development of novel nanoparticles for DDS, and establishment of Therapeutic modality for brain ischemia by use of these nanoparticles.
    • 批准号:
      22659010
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $1.98万
    • 财政年份:
      2010
    • 负责人:
      OKU Naoto
    • 依托单位:
    A novel targeting DDS for the treatment of autoimmune diseases and allergy
    • 批准号:
      20390014
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.4万
    • 财政年份:
      2008
    • 负责人:
      OKU Naoto
    • 依托单位:
    海外基金